Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Chi, Yihebali; Fang, Zhiwei; Hong, Xiaonan; Yao, Yang; Sun, Ping; Wang, Guowen; Du, Feng; Sun, Yongkun; Wu, Qiong; Qu, Guofan; Wang, Shusen; Song, Jianmin; Yu, Jianchun; Lu, Yongkui; Zhu, Xia; Niu, Xiaohui; He, Zhiyong; Wang, Jinwan; Yu, Hao; Cai, Jianqiang

doi:10.1158/1078-0432.ccr-17-3766

Public

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Published in Clinical Cancer Research • Jun 12, 2018

Authors:

Yihebali Chi

Zhiwei Fang

Xiaonan Hong

Abstract

Abstract Purpose: The prognosis for patients with refractory soft-tissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical and phase I studies. Patients and Methods: Patients 18 years and older, progressing after anthracycline-based chemotherapy, naïve ...

Subject

Medicine

Alveolar soft part sarcoma

Sarcoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!